Evidence map›Paper›PMID 36830959›Full record

ArticleBiomedicines2023

Minimal Collagen-Binding Epitope of Glycoprotein VI in Human and Mouse Platelets.

Chao Han, Pengxuan Ren, Medina Mamtimin, Linus Kruk, Edita Sarukhanyan, Chenyu Li, Hans-Joachim Anders, Thomas Dandekar, Irena Krueger, Margitta Elvers and 6 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Chao HanWalther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilian-University, 80336 Munich, Germany.
Pengxuan RenSchool of Life Science and Technology, Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai 201210, China.ORCID 0000-0001-6475-3974
Medina MamtiminWalther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilian-University, 80336 Munich, Germany.
Linus KrukWalther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilian-University, 80336 Munich, Germany.
Edita SarukhanyanDepartment of Bioinformatics, Biocenter, University of Würzburg, 97074 Würzburg, Germany.
Chenyu LiDivision of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilian-University, 80336 Munich, Germany.
Hans-Joachim AndersDivision of Nephrology, Department of Medicine IV, Hospital of the Ludwig-Maximilian-University, 80336 Munich, Germany.ORCID 0000-0003-2434-2956
Thomas DandekarDepartment of Bioinformatics, Biocenter, University of Würzburg, 97074 Würzburg, Germany.ORCID 0000-0003-1886-7625
Irena KruegerDepartment of Vascular and Endovascular Surgery, Heinrich-Heine University Medical Center, 40225 Düsseldorf, Germany.ORCID 0000-0001-8451-4188
Margitta ElversDepartment of Vascular and Endovascular Surgery, Heinrich-Heine University Medical Center, 40225 Düsseldorf, Germany.
Silvia GoebelAdvanceCOR GmbH, 82152 Martinsried, Germany.
Kristin AdlerAdvanceCOR GmbH, 82152 Martinsried, Germany.
Götz MünchAdvanceCOR GmbH, 82152 Martinsried, Germany.ORCID 0000-0002-5552-4923
Thomas GudermannWalther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilian-University, 80336 Munich, Germany.
Attila BraunWalther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilian-University, 80336 Munich, Germany.
Elmina Mammadova-BachWalther-Straub-Institute for Pharmacology and Toxicology, Ludwig-Maximilian-University, 80336 Munich, Germany.
Ludwig-Maximilians-Universität München · DEadvanceCOR (Germany) · DEDüsseldorf University Hospital · DEUniversity of Würzburg · DEGerman Center for Lung Research · DEShanghaiTech University · CN

Funding

Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit (BLGL) (project number 15-25)Deutsche Forschungsgemeinschaft CRC TRR152; AN372/20-2 and 30-1, 3 74031971 - TRR 240/Z2
6 · The paper itself

Abstract

Glycoprotein VI (GPVI) is a platelet-specific receptor for collagen and fibrin, regulating important platelet functions such as platelet adhesion and thrombus growth. Although the blockade of GPVI function is widely recognized as a potent anti-thrombotic approach, there are limited studies focused on site-specific targeting of GPVI. Using computational modeling and bioinformatics, we analyzed collagen- and CRP-binding surfaces of GPVI monomers and dimers, and compared the interacting surfaces with other mammalian GPVI isoforms. We could predict a minimal collagen-binding epitope of GPVI dimer and designed an EA-20 antibody that recognizes a linear epitope of this surface. Using platelets and whole blood samples donated from wild-type and humanized GPVI transgenic mice and also humans, our experimental results show that the EA-20 antibody inhibits platelet adhesion and aggregation in response to collagen and CRP, but not to fibrin. The EA-20 antibody also prevents thrombus formation in whole blood, on the collagen-coated surface, in arterial flow conditions. We also show that EA-20 does not influence GPVI clustering or receptor shedding. Therefore, we propose that blockade of this minimal collagen-binding epitope of GPVI with the EA-20 antibody could represent a new anti-thrombotic approach by inhibiting specific interactions between GPVI and the collagen matrix.

Indexed as

anti-thrombotic therapiesblood plateletscollagenGPVIthrombosis

Identifiers

PMID36830959
PMCPMC9952969
OpenAlexW4318824796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.